Top in ID: COVID-19 antibody regimen, measles vaccination
Click Here to Manage Email Alerts
Phase 3 trial results of Regeneron’s casirivimab and imdevimab regimen showed an 81.6% reduced risk for COVID-19 over 2 to 8 months of follow up compared with placebo. A report on the data was the top story in infectious disease last week.
Another top story was about a new report that revealed more than 22 million infants worldwide were not vaccinated against measles in 2020. Researchers said the findings, published in MMWR, suggest that this may lead to increases in deaths and complications related to measles.
Source: Adobe Stock
Read these and more top stories in infectious disease below:
Regeneron says antibody cocktail provides long-term protection from COVID-19
Regeneron said that a single dose of its antibody cocktail REGEN-COV reduced the risk for COVID-19 by nearly 82% up to 8 months after administration in a phase 3 trial. Read more.
22 million infants went unvaccinated against measles in 2020, report warns
In 2020, more than 22 million infants globally did not receive a first dose of measles vaccine — the largest number in 2 decades, according to a report published Wednesday in MMWR. Read more.
Urinary antigen testing linked to earlier antibiotic de-escalation in CAP
Among patients with community-acquired pneumonia, receipt of a positive pneumococcal urinary antigen test was associated with earlier de-escalation of antimicrobials compared with patients who received a negative test, according to a study. Read more.
Biden picks Califf to lead FDA again, asks for swift confirmation
President Joe Biden on Friday announced his intention to nominate cardiologist Robert Califf, MD, MACC, to lead the FDA for a second time. Read more.
Q&A: Biden’s power to mandate employee vaccination
On Sept. 9, President Joe Biden announced a six-pronged plan to combat a rise in COVID-19 cases that included federal vaccine mandates for roughly 100 million U.S. workers. Read more.